Press

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

Dec 20 • 4 min read

Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health disorders, today announced the closing of a $39 million Series B round of financing. The round was led by Prime Movers Lab with additional investment from Alumni Ventures, Palo Santo, Negev Capital, Route 66, JLS Fund, Satori Capital…

First Patient Dosed in Small Pharma’s Drug Interaction Study

Dec 19 • 2 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the first patient has been dosed in the Company’s Phase Ib drug interaction study. The study aims to assess the interaction between selective serotonin reuptake inhibitors and SPL026, the Company’s lead N,…

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

Dec 19 • 5 min read

atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”) Center for the Neuroscience of Psychedelics. The $2 million Fellowship Fund was announced in December 2021 to facilitate research into the potential of psychedelics to address unmet patient…

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

Dec 19 • 6 min read

Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani. Dear Fellow Shareholders: Clearmind’s overarching mission since inception has been to promptly bring our proprietary compound CMND-100 to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug…

Mydecine Innovations Group Announces Closing Under Share Subscription Agreement

Dec 19 • 2 min read

Mydecine Innovations Group Inc. (NEO: MYCO | OTC: MYCOF | FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement with a third-party…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435